Clinical Trials Directory

Trials / Unknown

UnknownNCT02327819

The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Tel-Aviv Sourasky Medical Center · Other Government
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Supplementation of BCAA found to reduce the risk of developing liver cancer, but the affect of BCAA on existing liver cancer is unknown. The participants (post curative intent surgery) will be supplemented with either BCAA/non-BCAA-enriched protein supplement. The intervantion will go on for 2 years or until a new liver tumor is found.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTBranched-chain amoni acids (BCAA)
DIETARY_SUPPLEMENTnon-BCAA protein supplement

Timeline

Start date
2015-01-01
Primary completion
2015-12-01
First posted
2014-12-30
Last updated
2014-12-30

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT02327819. Inclusion in this directory is not an endorsement.

The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer (NCT02327819) · Clinical Trials Directory